Hsp70/nitric oxide relationship in apoptotic modulation during obstructive nephropathy

Walter Manucha1, Patricia Vallés

  • 1Departamento de Patología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Centro Universitario, Mendoza, Argentina.

Insights

Kidney function relies on programmed cell death, or apoptosis, which is crucial for development and cell turnover. This review examines nitric oxide and Hsp70 interactions in regulating kidney cell death and oxidative stress responses during obstructive nephropathy.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Cellular Biology

Background:

  • Kidney function depends on cellular processes including development and turnover.
  • Apoptosis (programmed cell death) is vital for maintaining kidney integrity.
  • Obstructive nephropathy triggers complex mechanisms, including apoptosis, leading to kidney damage.

Purpose of the Study:

  • To review the interplay between nitric oxide and Heat Shock Protein 70 (Hsp70).
  • To explore the regulation of antiapoptotic mechanisms within the kidney.
  • To investigate protective oxidative stress responses in the context of kidney injury.

Main Methods:

  • Literature review focusing on nitric oxide signaling.
  • Analysis of Hsp70's role in cellular protection.
  • Examination of oxidative stress pathways in renal pathophysiology.

Main Results:

  • Nitric oxide and Hsp70 exhibit complex interactions influencing apoptosis.
  • Modulation of these pathways can impact renal tubular atrophy and cell loss.
  • Understanding oxidative stress responses is key to kidney protection.

Conclusions:

  • Nitric oxide and Hsp70 are critical regulators in kidney cell death pathways.
  • Targeting these interactions may offer therapeutic strategies for obstructive nephropathy.
  • Further research into protective oxidative stress mechanisms is warranted for kidney health.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...